Therapies in development for the treatment of migraine

Bibliography

• POP PH, GIERVELD CM, KARIS HA, TIEDINK HG: Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eui: .1. Neurol. (2002) 9:171–174.
   Google Scholar
• BRANDES JL: Global trends in migraine care: results from the MAZE survey, CNS. Drugs (2002) 16\(Suppl. 1):13–18.
   Google Scholar
• •A total of 5553 members of the general public in the UK, France, Germany, Italy and the US were interviewed by telephone and classified according to International Headache Society criteria, and the Migraine Disability Assessment Scale (MIDAS) questionnaire was used to assess the impact of migraine on work, home and social lives.
   Google Scholar
• LAUNER LJ, TERWINDT GM, FERRARI MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology (1999) 53:537–542.
   PubMed Web of Science ®Google Scholar
• HU XH, MARKSON LE, LIPTON RB, STEWART WE BERGER ML: Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. (1999) 159:813–818.
   PubMed Web of Science ®Google Scholar
• WEILLER C, MAYA, LIMMROTH V et al: Brain stem activation in spontaneous human migraine attacks. Nat. Med. (1995) 1:658–660.
   PubMed Web of Science ®Google Scholar
• ••Based on PET studies in migraineurs, thiskey paper established the role of the 'migraine generator' in the human brain stem.
   Google Scholar
• MARKOWITZ S, SAITO K, MOSKOWITZ MA: Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. Neurosci. (1987) 7:4129–4136.
   PubMed Web of Science ®Google Scholar
• ••Using radiolabelled bovine serum albuminadministered to guinea pigs, the authors demonstrated blood plasma extravasation from extracranial vessels following chemical, electrical or immunological stimulation.
   Google Scholar
• FERRARI MD, ROON KI, LIPTON RB, GOADSBY PJ: Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358: 1668-1675.
   Google Scholar
• ••This is the most comprehensive comparative meta-study of triptan drugs to date. It is based on raw patient data of all double-blind, randomised, controlled, clinical trials provided by pharmaceutical companies and the principal investigators of company-independent trials of oral triptans in migraine.
   Google Scholar
• MARCUS DA: Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans). Arch. Neurol. (2001) 58:1056–1058.
   PubMed Web of Science ®Google Scholar
• COMER MB: Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache (2002) 42\(Suppl. 2):S47–S53.
   Google Scholar
• BUCHAN P, KEYWOOD C, WADE A, WARD C: Clinical pharmacokinetics of frovatriptan. Headache (2002) (Suppl. 2):554–562.
   Google Scholar
• RAPOPORT AM, TEPPER SJ: Triptans are all different. Arch. Neurol (2001) 58:1479–1480.
   PubMed Web of Science ®Google Scholar
• RYAN R, GERAUD G, GOLDSTEIN J, CADY R, KEYWOOD C: Clinical efficacy of frovatriptan: placebo-controlled studies. Headache (2002) 42\(Suppl. 2):584–592.
   Google Scholar
• RAPOPORT A, RYAN R, GOLDSTEIN J, KEYWOOD C: Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache (2002) (Suppl. 2):574–583.
   Google Scholar
• EINER-JENSEN N, LARSEN L, DEPREZ S, STARNS E, SCHWARTZ S: Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. Biopharin. Drug Dispos. (2002) 22:213–219.
   Web of Science ®Google Scholar
• RAPOPORT A: The sumatriptan nasal spray: a review of clinical trials. Cephalalgia (2001) 21\(Suppl. 1):13–15.
   Google Scholar
• HERSHEY AD, POWERS SW, LECATES S, BENTTI AL: Effectiveness of nasal sumatriptan in 5- to 12-year-old children. Headache (2001) 41:693–697.
   PubMed Web of Science ®Google Scholar
• •Of interest, not only because of the route of administration, but also because many of the new migraine abortive agents have not been well evaluated in paediatric populations.
   Google Scholar
• ROTHNER AD, WINNER P, NETT R et al.: One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin. Thei: (2000) 22:1533–1546.
   PubMed Web of Science ®Google Scholar
• WINNER P, ROTHNER AD, SAPER Jet al.: A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics (2000) 106:989–997.
   Google Scholar
• TFELT-HANSEN P: Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia (2000) 20:137.
   PubMed Web of Science ®Google Scholar
• TREVES TA, KURITZKY A, HERING R, KORCZYN AD: Dihydroergotamine nasal spray in the treatment of acute migraine. Headache (1998) 38:614–617.
   PubMed Web of Science ®Google Scholar
• ROBBINS L: Stadol nasal spray for headache. Headache (2002) 42:386.
   PubMed Web of Science ®Google Scholar
• MELANSON SW, MORSE JW, PRONCHIK DJ, HELLER MB: Transnasal butorphanol in the emergency department management of migraine headache. Am. j Emerg. Med (1997) 15:57–61.
   PubMed Web of Science ®Google Scholar
• CADY R, CRAWFORD G, AHRENS S et al: Long-term efficacy and tolerability of rizatriptan wafers in migraine. Medscape General Medicine (2001) 3:1.
   PubMedGoogle Scholar
• DOWSON AJ, MACGREGOR EA, PURDY RA, BECKER WJ, GREEN J, LEVY SL: Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia (2002) 22:101–106.
   PubMed Web of Science ®Google Scholar
• DELEU D, HANSSENS Y: Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Clin. Pharmacol. (2000) 40:687–700.
   Google Scholar
• •The in vitro pharmacological properties, pharmacokinetics, clinical efficacy, drug interactions and adverse effects of almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and zolrnitriptan are evaluated and compared to surnatriptan.
   Google Scholar
• JHEE SS, SHIOVITZ T, CRAWFORD AW, CUTLER NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinet. (2001) 40:189–205.
   PubMed Web of Science ®Google Scholar
• •A good comparative review of the pharmacological properties of the newer triptan drugs.
   Google Scholar
• TOM B, DE VRIES P, HEILIGERS JP et al.: Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs. Cephalalgia (2002) 22:37–47.
   PubMed Web of Science ®Google Scholar
• JOHN GW, PAUWELS PJ, PEREZ M et al: F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. I Pharmacol Exp. Ther. (1999) 290:83–95.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE J, SOUBROUILLARD C, PARIS J, PISANO P, BUN 0: Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin. Pharmacol The]: (2000) 68:114–121.
   Google Scholar
• LONGMORE J, BOULANGER CM, DESTA B, HILL RG, SCHOFIELD WN, TAYLOR AA: 5-HT1D receptor agonists and human coronary artery reactivity in vitra crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br: J. Clin. Pharmacol. (1996) 42:431–441.
   Google Scholar
• RUSSELL MG, MATASSA VG, PENGILLEY R et al.: 3- [3-(Piperidin-1-yflpropyl]indoles as highly selective h5-HT(1D) receptor agonists. J. Med. Chem. (1999) 42:4981–5001.
   PubMed Web of Science ®Google Scholar
• FOZARD JR: The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraineMrch. mt. Pharmacodyn. The]: (1995) 329:111–119.
   Google Scholar
• •The evidence of a link between 5-1-1T, 5-HT2B/5-HT2c receptors and nitric oxide in migraine attack initiation is dicussed.
   Google Scholar
• BONHAUS DW, FLIPPIN LA, GREENHOUSE RJ et al.: RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br. J. Pharmacol (1999) 127:1075–1082.
   PubMed Web of Science ®Google Scholar
• MAY A, GOADSBY PJ: Substance P receptor antagonists in the therapy of migraine. Expert. Opin. Investig. Drugs (2001) 10:673–678.
   PubMed Web of Science ®Google Scholar
• ••The best current review on the titlesubject.
   Google Scholar
• LASSEN LH, HADERSLEV PA, JACOBSEN VB, IVERSEN HK, SPERLING B, OLESEN J: CGRP may play a causative role in migraine. Cephalalgia (2002) 22:54–61.
   PubMed Web of Science ®Google Scholar
• •The first significant published clinical study with CGRP in migraine.
   Google Scholar
• MA QP, HILL R, SIRINATHSINGHJI D: Colocalization of CGRP with 5-HT 1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Ear: Neurosci. (2001) 13:2099–2104.
   PubMed Web of Science ®Google Scholar
• DOODS H, HALLERMAYER G, WU D et al.: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol (2000) 129:420–423.
   PubMed Web of Science ®Google Scholar
• AIYAR N, DAINES RA, DISA J et at: Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. Pharmacol Exp. The]: (2001) 296:768–775.
   Google Scholar
• DIAMOND S, FREITAG F, PHILLIPS SB, BERNSTEIN JE, SAPER JR: Intranasal civamide for the acute treatment of migraine headache. Cephalalgia (2000) 20:597–602.
   PubMed Web of Science ®Google Scholar
• MA QP: Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport (2001) 12:1589–1591.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, CLASSEY JD: Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brant Res. (2000) 875:119–124.
   PubMed Web of Science ®Google Scholar
• STORER RJ, GOADSBY PJ: Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience (1999) 90:1371–1376.
   PubMed Web of Science ®Google Scholar
• CUTRER FM: Antiepileptic drugs: how they work in headache. Headache (2001) 41\(Suppl. 1):53–S10.
   Google Scholar
• •A good review of the utility of current anticonvulsants in severe headache, including migraine.
   Google Scholar
• STOREY JR, CALDER CS, HART DE, POTTER DL: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache (2001) 41:968–975.
   PubMed Web of Science ®Google Scholar
• LABINER DM: DP-VPA D-Pharm. Curt Opin. Investig. Drugs. (2002) 3:921–923.
   Google Scholar
• GOADSBY PJ, HOSKIN KL, STORER RJ, EDVINSSON L, CONNOR HE: Adenosine Al receptor agonists inhibit trigeminovascular nociceptive transmission. Brain (2002) 125:1392–1401.
   PubMed Web of Science ®Google Scholar
• HONEY A, BLAND-WARD PA, ALDERTON WK, FENIUK W, HUMPHREY PPA: The nNOS inhibitor, GW289013, inhibits neurogenic vasodilation in the anesthetized rat. Br. J. Pharmacol (2001) 134:102P
   Google Scholar
• TERWINDTG, KORS E, HAAN J et al.: Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch. Neurol (2002) 59:1016–1018.
   PubMed Web of Science ®Google Scholar
• KORS EE, VAN DEN MAAGDENBERG AM, PLOMP JJ, FRANTS RR, FERRARI MD: Calcium channel mutations and migraine. Curt Opin. Neurol (2002) 15:311–316.
   PubMed Web of Science ®Google Scholar
• LEA RA, CURTAIN RP, HUTCHINS C, BRIMAGE PJ, GRIFFITHS LR: Investigation of the CACNA1A gene as a candidate for typical migraine susceptibility. Am. J. Med. Genet (2001) 105:707–712.
   PubMed Web of Science ®Google Scholar
• WESSMAN M, KALLELA M, KAUNISTO MA et al.: A susceptibility locus for migraine with aura, on chromosome 4q24. Am. J Hum. Genet. (2002) 70:652–662.
   PubMed Web of Science ®Google Scholar
• MCCARTHY LC, HOSFORD DA, RILEY JH et al: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics (2001) 78:135–149.
   PubMed Web of Science ®Google Scholar
• BRAIN SD, POYNER DR, HILL RG: CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine? Trends Pharmacol. Sci. (2002) 23:51–53.
   Google Scholar